Cancer-Associated Fibroblasts as Another Polarized Cell Type of the Tumor Microenvironment by Martin Augsten
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW ARTICLE
published: 27 March 2014
doi: 10.3389/fonc.2014.00062
Cancer-associated fibroblasts as another polarized cell type
of the tumor microenvironment
Martin Augsten*
Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden
Edited by:
Jozsef Dudas, Medical University
Innsbruck, Austria
Reviewed by:
Jozsef Dudas, Medical University
Innsbruck, Austria
Rosa Noguera, University of Valencia,
Spain
*Correspondence:
Martin Augsten, Department of
Oncology-Pathology, CCK R8:03,
Karolinska Institutet, Stockholm 171
76, Sweden
e-mail: martin.augsten@ki.se
Tumor- or cancer-associated fibroblasts (CAFs) are one of the most abundant stromal cell
types in different carcinomas and comprise a heterogeneous cell population. Classically,
CAFs are assigned with pro-tumorigenic effects stimulating tumor growth and progression.
More recent studies demonstrated also tumor-inhibitory effects of CAFs suggesting that
tumor-residing fibroblasts exhibit a similar degree of plasticity as other stromal cell types.
Reciprocal interactions with the tumor milieu and different sources of origin are emerg-
ing as two important factors underlying CAF heterogeneity. This review highlights recent
advances in our understanding of CAF biology and proposes to expand the term of cel-
lular “polarization,” previously introduced to describe different activation states of various
immune cells, onto CAFs to reflect their phenotypic diversity.
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INTRODUCTION
Tumors display an organ-like structure and are composed of recip-
rocally interacting cell types including cancer-initiating cells, more
or less differentiated cancer cells, extracellular matrix, and a variety
of stromal cells such as endothelial cells, immune cells, pericytes,
adipocytes, and fibroblasts. Tumors produce a multitude of dif-
ferent factors such as growth factors, cytokines, and chemokines
that affect the phenotype and function of tumor-resident cells
and impact on the composition and texture of the extracellu-
lar matrix, thereby modulating, e.g., tumor stiffness. Among the
tumor-derived, secreted factors are various signaling mediators
that promote tumor malignancy through local and systemic sig-
nals, i.e., these factors can affect tumor-distant tissues and organs.
Some of those signals are known to act on the bone-marrow and
stimulate the release of bone-marrow derived cells (BMCs) that,
e.g., prepare the pre-metastatic niche for seeding cancer cells and
support their survival and outgrowth in the new soil (1, 2). The
various cell types of a tumor exhibit an enormous grade of plas-
ticity when exposed to the cocktail of tumor-derived factors. For
example, cancer cells acquire novel properties ensuring their sur-
vival, enabling their expansion, and enhancing their malignant
behavior (3). Depending on the type of stimuli, cells of the tumor
microenvironment can adopt different activation states that are
associated with phenotypes ranging from tumor promotion to
tumor suppression (4).
Cancer-associated fibroblasts (CAFs), originally introduced as
carcinoma-associated fibroblasts (5), represent one of the most
abundant stromal cell types of several carcinomas including breast
and prostate cancer. CAFs are activated fibroblasts that share sim-
ilarities with fibroblasts stimulated by inflammatory conditions
or activated during wound healing (6, 7). Different cellular ori-
gins and tumor-derived factors shape the phenotype of CAFs
and contribute to their appearance as heterogeneous cell pop-
ulation with distinct subtypes. Besides their established role as
promoter of tumor growth and progression, recent data obtained
from in vitro co-cultures and in vivo xenograft models, suggest a
tumor-inhibitory role of CAFs. This review will discuss the differ-
ent elements that, taken together, contribute to the plasticity and
diverse phenotypes of CAFs.
CELLULAR MARKER DEFINE CANCER-ASSOCIATED
FIBROBLASTS AS A HETEROGENEOUS CELL POPULATION
Comparative gene expression profiling of tissue-derived nor-
mal fibroblasts (NFs) and CAFs and other approaches revealed
that CAFs produce a variety of factors which are lower or not
expressed by the normal counterparts. As a sign of their activa-
tion, CAFs produce several mesenchyme-specific proteins such
as fibroblast-specific protein (FSP-1), also known as S100A4, the
fibroblast-activating protein (FAP), vimentin, and alpha-smooth
muscle actin (α-SMA), the prototypical marker for myofibrob-
lasts. CAFs are also a rich source of different secreted factors
such as cytokines, chemokines (e.g., IL-6, CXCL8, CXCL12), and
growth factors including vascular endothelial-derived growth fac-
tor (VEGF), transforming growth factor beta (TGF-β), hepa-
tocyte growth factor (HGF), epidermal growth factor (EGF),
or fibroblast growth factor (FGF), and express receptors such
as platelet-derived growth factor receptor alpha (PDGFRα) and
platelet-derived growth factor receptor beta (PDGFRβ). These sol-
uble factors are involved in paracrine signaling or activate CAFs
in autocrine loops, thereby contributing to the constitution of
the CAF phenotype. Furthermore, CAFs play an important role
in remodeling of the extracellular matrix by expressing a wide
variety of matrix-components and matrix-remodeling enzymes
such as neuron glial antigen (NG2), tenascin C, type I collagen,
fibronectin, or MMP-1/stromelysin-1 (8, 9).
Several intracellular and plasma membrane-associated proteins
such as α-SMA, vimentin, and PDGFRβ have been used as CAF
markers to detect CAFs in tumor tissue. These markers were also
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used in functional studies to purify CAFs from tissue or to study
their role in tumor growth and metastasis (10–14). A recent study
by Orr et al., revealed additional markers such as ASPN, ZEB1,
and OGN that distinguish prostate CAFs from their normal coun-
terparts (15). The glycoprotein podoplanin was also suggested as
another, novel CAF-marker that has been shown to have prognos-
tic significance for different types of tumors (16, 17). However,
all the CAF markers described so far are apparently not unique
for this cell type and are expressed by other cell types of a tumor,
reflecting the plasticity of stromal cells. For example, podoplanin is
also a marker of lymphatic vessels and can be expressed by cancer
cells, and expression of the PDGFRβ is also a feature of pericytes
(16, 18). This makes it difficult to purify CAFs on basis of mark-
ers from other cells like adipocytes, endothelial cells, or pericytes
that share expression of those proteins. Thus, many cancer studies
claiming to describe CAF-specific effects, and relying on the use of
shared markers, might be flawed by inclusion of other cell types. If
there is not a single CAF-specific marker perhaps a combination
of different markers will eventually help to better define the CAF
population in the future.
Fibroblasts comprise a heterogeneous population of mesenchy-
mal cells. NFs exhibit a “topographic differentiation” pattern, i.e.,
fibroblasts express a transcriptional program associated with their
anatomical location (19). Accordingly, topographic differentia-
tion is likely to affect the appearance of CAFs and contributes
to (systematic) differences among CAFs from different anatom-
ical sites. But also within the same type of tissue, CAF markers
are not uniformly expressed on these cells and rather define dis-
tinct CAF subsets. The study by Sugimoto et al. was the first
to describe different CAF-subtypes based on expression analy-
sis of FSP-1/S100A4, PDGFRβ, NG2 α-SMA in a pancreatic and
a breast cancer mouse model (9). Interestingly, the findings from
both tumor models were remarkably similar and revealed one
CAF-subtype that is characterized by co-expression of α-SMA,
PDGFRβ, and NG2, while FSP-1 expression defines another CAF-
subtype. Furthermore, gene expression analysis demonstrated a
breast cancer subtype-specific molecular profile of CAFs (20).
Despite these efforts, it is still not known how many CAF-subtypes
exist in a certain tumor type and how the tentative CAF subsets
are associated with different tumor compartments. The question
if different, marker-defined CAF subsets exert different functions
is emerging and has been started to address (14, 21–24).
TO THE ROOTS OF CANCER-ASSOCIATED FIBROBLASTS
Different elements contribute to the heterogeneity of CAFs includ-
ing the tissue type in which the tumor grows, the local paracrine
environment, and the cell type-of-origin. One significant source
for CAFs is local fibroblasts and tissue-resident fibroblast precur-
sor cells that become incorporated into the growing tumor by
tumor-derived stimulants (25).
As introduced above, tumors produce and release a variety of
factors such as chemokines with long-ranging effects that mod-
ulate the phenotype of cells in a tumor-distant environment and
eventually attract cells from a distant site into the tumor. Here, the
bone-marrow attracted much attention as a site that is subjected
to extensive changes by tumor-derived systemic signals (2, 26).
Tumor-activated BMCs are implicated in the formation of the
pre-metastatic niche and can also differentiate into CAFs upon
recruitment into tumors (27–29). Furthermore, once entered the
tumor BMCs have been shown to attract local fibroblast that adopt
a CAF phenotype in the tumor milieu (25). Among the BMCs,
mesenchymal stem cells (MSCs) attracted much attention because
they can differentiate in a variety of different stromal cells like
CAFs depending on the factors and structures they are exposed to
(8, 30). In the tumor microenvironment, MSCs not only differen-
tiate into CAFs but can, for example, also give rise to endothelial
and various immune cells (31).
The conversion of differentiated cells represents another source
of CAFs and provides an impressive example for the enormous
plasticity that cells exhibit when exposed to the environment of
a tumor. Epithelial-to-mesenchymal transition (EMT), one of the
developmental processes hijacked by tumors, contributes to an
invasive, pro-metastatic phenotype of cancer cells and gives rise
to mesenchymal-like cells that share marker and properties with
CAFs (32). Interestingly, CAF-derived signals in turn can also pro-
mote EMT and contribute to cancer stemness (33–35). In an EMT-
related process termed endothelial-to-mesenchymal transition
(EndMT), tumor-derived signals stimulate trans-differentiation of
endothelial cells to adopt a CAF-like phenotype, characterized by
expression of fibroblast marker (α-SMA, FSP-1) and the endothe-
lial marker CD31 (36). Although not formally established, vessel-
associated, α-SMA-expressing pericytes have been suggested as an
additional origin for CAFs (18). Furthermore, adipocytes can be
subjected to the instructive force of the tumor milieu and also
contribute to the CAF population (37).
The different sources represent an important component that
contributes to the heterogeneity of CAFs and contributes to the
difficulty to distinguish CAFs from other cell types expressing sim-
ilar markers. However, little is known if different tumor types share
certain sources for CAFs, if the different cellular origins give rise
to specific CAF-subtypes and to what extent the different sources
contribute to the whole of the CAF population of a given tumor.
A recent study analyzing the fraction of α-SMA-positive myofi-
broblasts in kidney fibrosis determined that approximately 65%
of myofibroblasts in inflamed tissue are locally resident fibroblast
that become activated under these conditions. The remaining 35%
of myofibroblasts are derived from BMCs recruited into the kidney
by pro-inflammatory signals (38). In the context of cancer, Quante
et al. found that approximately 20% of the myofibroblasts in an
inflammation-induced gastric cancer model were bone-marrow
derived (29). In a pancreatic cancer model, BMCs contributed with
up to 40% to the α-SMA-positive CAF population (28). However,
in a breast cancer model studying systemic signaling, myofibrob-
lasts in tumors growing at a distant site were derived from local
sources but not from BMCs (25), indicating tissue type or cancer
model-specific differences. Furthermore, EndMT can account for
up to 12% of α-SMA-positive and 30% of FSP-1-positive CAFs
in a murine melanoma model (36). And Kidd et al. found that
approximately 29% of α-SMA-positive fibroblasts were derived
from breast adipose tissue (39). The latter study also suggested
that the relative proportion of different CAF-subtypes varies in a
tumor (39).
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TUMOR-PROMOTING EFFECTS OF CANCER-ASSOCIATED
FIBROBLASTS
Intensive research over the last decade revealed that CAFs play
a pivotal role in the multi-step process of tumorigenesis, pro-
metastatic signaling, and metastatic growth, impacting on each
step. Although still under debate if CAFs by themselves can induce
malignant transformation of “normal” epithelium (lacking onco-
genic mutations), there is compelling evidence that CAFs promote
tumor development and progression from pre-malignant stages (5,
14), stimulate metastasis (40, 41), and support the outgrowth of
disseminated cancer cells at the site of metastasis (42). It has also
been recognized that different CAF subsets, such as those charac-
terized by α-SMA or FSP-1, display a pro-tumorigenic phenotype
(14, 43). However, it is less clear if fibroblast subpopulations
stimulate distinct aspects during malignancy.
The pro-tumorigenic activity of CAFs includes strong paracrine
effects impacting on different cell types present in the tumor
(Figure 1). Direct stimulation of cancer cells by CAF-derived sig-
nals promotes, e.g., cancer cell proliferation (44, 45), migration,
invasion (46–50), and the adoption of a cancer stem cell pheno-
type by inducing EMT (51–55). Interestingly, CAFs have also been
shown to pave the way for cancer cells, providing tracks for cancer
cells to migrate and invade surrounding tissue (56, 57). Further-
more, CAFs secrete a variety of pro-inflammatory factors (21, 58)
leading to the recruitment and promotion of immunosuppres-
sive (59) and tumor-promoting immune cells (60), thereby con-
tributing to the establishment of a pro-inflammatory, immune-
suppressive, tumor-permissive environment. The various pro-
tumoral activities of CAFs are comprehensively covered by a
number of recent reviews that are recommended for further
reading (61–64).
Along with these studies an ever-expanding list of
CAF-derived, pro-tumorigenic factors (e.g., growth fac-
tors, cytokines, chemokines, matrix-components, and matrix-
remodeling enzymes) and associated signaling pathways (e.g.,
TGF-β, Wnt, Hedgehog) have been identified. Many of these
factors stimulate several CAF-activities and affect multiple cell
types. For example, the chemokine CXCL12 has been shown to
promote tumor growth by affecting breast cancer cell growth
and by stimulating the recruitment of endothelial precursor cells
(EPCs) into the tumor (65). Some CAF-derived factors such as
the chemokine CXCL14 exert autocrine effects on fibroblasts (66),
while other CAF-derived factors act in a paracrine manner stim-
ulating cancer and stromal cells (e.g., endothelial cells, immune
cells), and are involved in the recruitment of host cells into the
tumor (29, 40, 67). Moreover, CAF-derived matrix-components
and matrix-remodeling enzymes can, e.g., increase the stiffness
of solid tumors thereby enhancing aggressiveness and stimulating
metastasis (68–70).
TUMOR-SUPPRESSIVE EFFECTS OF TUMOR-RESIDENT
FIBROBLASTS
Tumor promotion is the dominating functional property allo-
cated to CAFs, and together with enhanced proliferation used as a
marker to discriminate CAFs from NFs (71). In contrast, NFs have
the capacity to suppress growth and progression of pre-malignant
lesions (72).
Recent data suggest that this ability can also be a feature
of tumor-resident fibroblasts (Figure 1). For example, primary
fibroblasts established from normal and cancer tissue can inhibit
the growth of a panel of co-cultured cancer cells in vitro (73).
More mechanistic insight was recently provided by Chang et al.
using primary fibroblasts established from breast tissue (74).
Both, NFs and CAFs expressing the ligand Slit2 inhibited the
tumorigenicity of breast cancer cells expressing the corresponding
Robo1-receptor on their surface. Ligand-induced Robo1 activa-
tion interfered with PI3K- and β-catenin signaling in cancer cells
and diminished their malignant potential. Previously, it was shown
that Slit-stimulated signaling also inhibits the pro-tumorigenic
SDF1/CXCR4-signaling pathway (75, 76). In contrast, the activ-
ity of breast cancer cells lacking Robo1-expression was rather
stimulated by Slit2-expressing fibroblasts, demonstrating that the
functional outcome of CAF activity is decided on the level of
the malignant cells (74). Importantly, tissue analyses revealed the
FIGURE 1 |Tumor-stimulatory and tumor-inhibitory effects of CAFs.
Fibroblasts present in the tumor stroma (CAFs) are predominantly
assigned with a tumor-promoting function. CAFs (shown in red)
stimulate cancer cell survival, growth, and invasion, enhance the
stiffness of the extracellular matrix, contribute to angiogenesis by
releasing pro-angiogenic factors, contribute to a pro-inflammatory
milieu, and impact on the activation state of various immune cells.
More recent data demonstrate that tumor-resident fibroblast (depicted
in yellow) can also confer tumor-suppressive effects. However, the
mechanisms underlying this inhibitory phenotype are not known but
may involve direct inhibition of cancer cells and modulation of immune
cell behavior.
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presence of Slit2-expressing fibroblasts in breast tumor tissue thus
validating the relevance of these CAFs in human disease and sug-
gesting Slit2 as a potential effector of this tumor-inhibitory CAF-
subtype. Furthermore, Slit expression was demonstrated to have
prognostic significance predicting overall survival and occurrence
of metastasis (74).
In another study, Green et al. observed that fibroblast-derived
Wnt3a could promote but also inhibit the growth of different,
orthotopically growing patient-derived breast xenograft tumors
(77). However, the molecular basis for the opposing behavior of
Wnt3a-expressing fibroblasts remained unresolved. Nevertheless,
these recent studies provide first clear experimental evidence that
the same type of CAF can exert a broader spectrum of activities
ranging from tumor stimulation to tumor inhibition. Moreover,
the impact of CAFs on tumorigenesis appears to be less depen-
dent on the instructive role of CAFs but is rather governed by the
interacting malignant compartment. This illustrates the strong
context-dependent action of CAFs in the tumor milieu as previ-
ously described for other stromal cells such as immune cells and
pericytes (4, 18).
The wide range of fibroblast activities is defined by their molec-
ular makeup that is controlled by an intrinsic expression program
related to the fibroblast site of origin, and modulated by external
cues. Accordingly, CAFs express a variety of different factors that
contribute to shape the environment, including pro-tumorigenic
factors that potently stimulate tumor growth. However, the same
CAFs may eventually co-express factors that by themselves sup-
press the action of tumor-resident cells. For example, primary
prostate CAFs express several tumor-promoting factors but at the
same time molecules have been shown to suppress cancer cell
growth, migration, and invasion (Martin Augsten, unpublished
observation). Furthermore, individual CAF-derived factors also
act in a cell type and/or tumor stage-dependent manner. For exam-
ple, the chemokine CXCL14 is expressed by cancer cells and CAFs
of different tumor types, and CXCL14 acting through fibroblasts
exerts tumor-promoting effects in vivo by stimulating angiogen-
esis and macrophage infiltration (66, 78). In contrast, CXCL14
expressed by cancer cells inhibits the growth of xenograft tumors
derived from different origins (79, 80). Similarly, Wnt signaling
has been shown to critically contribute to tumorigenesis (42, 81).
On the contrary, the fibroblast-derived Wnt-ligand Wnt3a can
promote and inhibit breast cancer tumor growth by yet unknown
mechanisms (77). Furthermore, TGF-β, for which CAFs are an
important source, is known to suppress tumor initiation and
early tumor growth but promotes tumor progression and metas-
tasis (82, 83). As discussed above, Slit2-induced Robo1 signaling
was identified as one mechanism by which CAFs exert a tumor-
suppressive effect (74). Thus, it will be interesting to elucidate
the molecular mechanisms underlying the differential action of
other CAF-derived factors such as Wnt3a, CXCL14, and GDF15,
a divergent member of the TGF-β superfamily. Further studies
should aim to understand the relative contribution of inhibitory
and stimulatory signals to the CAF phenotype and analyze the
expression pattern and kinetics of these signals during the course
of disease.
Although the potential tumor-inhibiting effect of CAFs is by far
less studied as their tumor-promoting activity, the data available
imply that CAFs exhibit a much broader spectrum of activities
than previously demonstrated. CAFs and CAF-derived factors
strongly act in a context-dependent fashion, and their tumor-
promoting and/or tumor-inhibiting activity is determined by the
intrinsic properties of CAFs but also depends – perhaps to an
even larger extent – on how these signals are processed by the
tumor environment, i.e., the type and/or the state of malignant
and other stromal cell populations. In that sense, CAFs retain fea-
tures of “normal” fibroblasts (fibroblasts in a tumor-free host)
that act as sensors of their environment and await activation by
external cues such as TGF-β, PDGF, IL-1. Of note, this is not to
confuse fibroblasts for an exclusively passively acting cell type (that
solely integrates external signals) since fibroblasts including CAFs
instruct their environment (normal and malignant epithelium)
upon stimulation (5, 72).
ASSIGNING THE POLARIZATION CONCEPT TO CAFs
The plasticity and emerging functional divergence of CAFs chal-
lenges our current definition of CAFs as a tumor-resident stromal
cell type assigned with tumor-promoting activity. Other cells of
the tumor microenvironment such as immune cells display also an
enormous grade of plasticity, and the term “polarization” has been
introduced to describe different activation states that immune cells
adopt in response to different external cues (4). Type I and type
II mark the two ends of the polarization spectrum, and repre-
sent distinct cellular lineages associated with different markers
and opposing activities in tumors. In the complex, heterogenic
(micro)milieu of a tumor immune cells apparently move in a
continuum of activation states between type I and type II.
Macrophages provide an illustrative example and can be
polarized into type I (“M1”) and type II (“M2”) macrophages,
respectively. While M1-polarized macrophages exert tumor-
suppressive effects, M2-polarized macrophages, called tumor-
associated macrophages (TAMs), promote tumor growth and pro-
gression (84, 85). Importantly, the polarization of macrophages
can be controlled by specific factors that are derived from
autocrine and/or paracrine signaling. For example, treatment of
macrophages with TNF-α, IFN-γ, and LPS in vitro induces type I
polarization, while macrophages adopt a type II phenotype under
the influence of IL-4, IL-10, and IL-13 (86). Polarization appears
to be a more general phenomenon because also various other
immune cells such as T-cells, dendritic cells, and neutrophils can
adopt different activation states under the influence of a tumor
(87–89). Interestingly, the different tumor-associated cell types
actively regulate the polarization status of each other. For example,
CAF-derived signals can promote polarization of CD4+ T-cells to
adopt a tumor-supportive, Th2 phenotype that is associated with
enhanced infiltration of TAMs and regulatory T (Treg) cells (90).
Furthermore, CAFs secrete IL-6 and CCL2 thereby promoting the
development of M2-macrophages (21, 60).
As introduced in the previous chapters, the phenotype of
tumor-associated fibroblasts is shaped by two components: the
type of cell giving rise to CAFs and the local environment CAFs are
embedded in. Exposure of fibroblasts to growth factors, cytokines,
reactive oxygen species (ROS), or a stiff matrix can induce a CAF
phenotype characterized by, e.g., α-SMA expression and endowed
with the ability to promote tumor growth and progression (33,
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68). On the contrary, the pro-tumorigenic action of CAFs can
be reverted by exposure to certain tumor-inhibitory factors such
as TGFBI (43), and tumor-resident fibroblasts can suppress tumor
growth in a proper microenvironment (74, 77). These recent devel-
opments in the field extend our current view on CAFs and provide
in vivo evidence of a similar degree of plasticity of tumor fibrob-
lasts as previously shown for different tumor-associated immune
cells.
Thus, I would like to propose to take on the concept of “polar-
ization” used in the context of immune cells and extend this
concept onto CAFs. Hence, the term “CAFs” defines a popula-
tion of fibroblasts present within the tumor or associated with the
tumor margin but does not, in contrast to the original definition,
assign a particular function to these cells. It seems to be about time
to revisit our definition on CAFs to adopt that to the increasing
knowledge around this cell type. Li et al. discussed the “two-faced
characteristics of fibroblasts in tumor stroma” in a recent review
(61). In an effort to better reflect the dynamic state of tumor-
associated fibroblasts, Mader et al. introduced the term “CAF
state” to describe the marker-based heterogeneity of these cells
(91). The herein proposed concept of “CAF polarization” high-
lights the functional heterogeneity of CAFs and proposes that the
different activation states of CAFs are associated with different, as
yet poorly described marker. Thus, both definitions are not mutual
exclusive but rather aim to provide a starting point to interconnect
CAF-marker with specific functional phenotypes.
FIGURE 2 | Properties of polarized CAFs. Depending on the type of signals,
intra-tumoral fibroblasts can be polarized thereby adopting different activation
states. Type II polarized fibroblasts (F2) differentiate into pro-tumorigenic
fibroblasts under the influence of, e.g., growth factors and chemokines (called
“inducer”). Signaling induced by CXCL14, hedgehog (Hh), or TGF-β activates
transcription factors that induce a program controlling the expression of a
variety of “effector”-molecules (matrix-components, matrix-remodeling
enzymes, growth factors, and cytokines) that in turn deploy pro-tumorigenic
effects by stimulating other cells in the environment of the local tumor and
beyond. In contrast, type I polarized fibroblasts (F1)-expressing molecules
such as Wnt3a and Slit2 can exhibit tumor-inhibitory effects by suppressing
the action of cancer cells. About the exogenous signals and transcription
factors involved in establishing the tumor-suppressive phenotype can only be
speculated so far. Potential inducers of type I-CAFs are TNF-α and LPS that
have been shown to stimulate Wnt3a and chemokine expression,
respectively (92).
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Adopting the style introduced for the different polarized
immune cells, CAFs will be divided into two functionally different
subtypes: F1- and F2-polarized fibroblasts (Figure 2). F1 repre-
sents type I-CAFs displaying tumor-inhibitory effects while F2
refers to type II-CAFs that exhibit tumor-promoting properties.
The obvious heterogeneity of CAFs and the recent findings on
Slit2- and Wnt3a-expressing, tumor-suppressive fibroblasts (74,
77) suggest that: (1) F1 and F2 represent the two extremes of a
spectrum of different phenotypes that CAFs can adopt and (2)
the polarization of CAFs stays under the control of the tumor
(micro)environment. In contrast to polarized immune cells where
several marker associated with either the type I or the type II sub-
type have been described, the marker/function relationship for
CAFs is much less characterized. Thus, the molecular makeup of
polarized fibroblasts, and the F1-type in particular, remain largely
elusive (Figure 2). Because the action of CAFs depends on the
nature of the interacting cell type it appears as an important future
task to identify marker associated with distinct CAF activation
states. Further studies should also aim to address if these activation
states are associated with a specific tumor stage.
CONCLUDING REMARKS
Much progress has been made in our understanding of CAFs
and revealed their multifaceted contributions to tumor develop-
ment, progression, and metastasis. A tumor-inhibitory action of
this cell type is also emerging but needs further validation. The
findings together imply that CAFs confer a much broader range
of action than previously thought and exhibit a similar degree of
plasticity as described for other cells of the tumor microenviron-
ment. Expanding the concept of cellular polarization to CAFs, as
proposed here, will accommodate for the functional diversity of
CAFs and aims to provide a framework to delineate unresolved
questions around the different CAF phenotypes. For example,
it is not clear which factors induce and determine certain CAF-
subtypes. An important task that has begun to be addressed
is to catalog the different CAF-subtypes present within a given
tumor type and across different types of tumors. However, it
is unclear how many CAF populations exist, and which marker
are associated with the tumor-promoting and tumor-inhibiting
phenotype, respectively. Addressing these questions will help to
reveal if populations of tumor-inhibitory CAFs are always present
in the tumor microenvironment, and if this population can be
activated or strengthened to limit initial and progressive tumor
growth. Of note, the recent data implicate that the tumor envi-
ronment defines the polarization status of CAFs that will adopt
a tumor-permissive, tumor-promoting, or tumor-inhibitory phe-
notype depending on the stimuli. It is likely, yet to be substantiated,
that certain tumor-derived factors alone or in a combination will
shift the CAF polarization status, in extreme scenarios from type I
to type II or vice versa. Considering the heterogeneity of a tumor
(93), a certain CAF-subtype might exhibit suppressive effects in a
certain microenvironment of the tumor while acting stimulatory
in another. Thus, a deeper and more profound understanding of
CAF biology is required if CAFs will be successfully explored as
therapeutic targets.
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